

Interpretable antibody-antigen interaction prediction by introducing route and priors guidance

Yutian Liu^{1†}, Zhiwei Nie^{2,3†}, Jie Chen^{2,3*}, Xinhao Zheng⁴,
 Jie Fu⁵, Zhihong Liu⁶, Xudong Liu², Fan Xu³, Xiansong Huang³,
 Wen-Bin Zhang^{7*}, Siwei Ma^{1*}, Wen Gao^{1,3}, Yonghong Tian^{2,1,3*}

¹School of Computer Science, Peking University, China.

²School of Electronic and Computer Engineering, Peking University, Shenzhen, China.

³Peng Cheng Laboratory, Shenzhen, China.

⁴Department of Computer Science and Engineering, Shanghai Jiao Tong University, China.

⁵Hong Kong University of Science and Technology, Hong Kong, China.

⁶Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, China.

⁷Beijing National Laboratory for Molecular Sciences, Key Laboratory of Polymer Chemistry & Physics of Ministry of Education, Center for Soft Matter Science and Engineering, College of Chemistry and Molecular Engineering, Peking University, China.

*Corresponding author(s). E-mail(s): jiechen2019@pku.edu.cn;
wenbin@pku.edu.cn; swma@pku.edu.cn; yhtian@pku.edu.cn;

[†]These authors contributed equally to this work.

Abstract

With the application of personalized and precision medicine, more precise and efficient antibody drug development technology is urgently needed. Identification of antibody-antigen interactions is crucial to antibody engineering. The time-consuming and expensive nature of wet-lab experiments calls for efficient computational methods. Taking into account the non-overlapping advantage of current structure-dependent and sequence-only computational methods, we propose an interpretable antibody-antigen interaction prediction method, S3AI. The

31 introduction of structural knowledge, combined with explicit modeling of chem-
32 ical rules, establishes a 'sequence-to-function' route in S3AI, thereby facilitating
33 its perception of intricate molecular interactions through providing route and
34 priors guidance. S3AI significantly and comprehensively outperforms the state-
35 of-the-art models and exhibits excellent generalization when predicting unknown
36 antibody-antigen pairs, surpassing specialized prediction methods designed for
37 out-of-distribution generalization in fair comparisons. More importantly, S3AI
38 captures the universal pattern of antibody-antigen interactions, which not only
39 identifies the CDRs responsible for specific binding to the antigen but also
40 unearths the importance of CDR-H3 for the interaction. Structure-free design and
41 superior performance make S3AI ideal for large-scale, parallelized antibody opti-
42 mization and screening, enabling the rapid and precise identification of promising
43 candidates within the extensive antibody space.

44 1 Introduction

45 As the important immune molecules of the human immune system [1], antibodies are a
46 specialized type of protein with the primary role of recognizing and combating invading
47 pathogens [2, 3]. The interaction between antibodies and antigens is characterized by
48 a remarkable specificity and plays a pivotal role in this immunological process [3].
49 Therefore, humans continue to explore methods for preparing antibodies to develop
50 antibody drugs and try to apply them in clinical treatments [4, 5]. In recent years,
51 the research and development of antibody drugs have entered a new stage, driven
52 by the continuous development of technologies such as genomics [6], proteomics [7],
53 and immunology [8]. Currently, antibody design methods with higher precision and
54 efficiency are urgently needed to meet the promotion and application of personalized
55 treatment and precision medicine [9, 10].

56 The core of improving the design efficiency of antibody drugs lies in estimating
57 the interaction strength of antibodies and antigens. The interaction strength between
58 an antibody and an antigen extends beyond a mere binary interaction; it should be
59 characterized as a continuous variable. Quantified by metrics such as the dissociation
60 constant (K_d) or the half-maximal inhibitory concentration (IC_{50}), this continuum
61 encapsulates the depth and strength of the interaction. Although there have been
62 several conventional wet-lab experiments [11–14] to estimate the interactions between
63 antibodies and antigens, they remain expensive and time-consuming. This presents a
64 significant barrier to thoroughly exploring the extensive antibody optimization space,
65 limiting the identification of novel and potentially more effective antibody candidates.
66 Therefore, efficient computational methods are urgently needed to predict antibody-
67 antigen interaction (AAI) to promote antibody optimization and screening.

68 As shown in Fig.1a, current computational methods, especially deep-learning meth-
69 ods, can be mainly divided into structure-dependent and sequence-only methods for
70 characterizing Antibody-Antigen Interactions (AAI). The former exhibits lower task
71 complexity since the model takes protein tertiary structure as input, which is closely




Fig. 1 Our motivation and methodology. Route and priors guidance are designed to facilitate interpretable prediction of antibody-antigen interactions. **a**, Two major categories of methods currently used for antibody-antigen interaction prediction are sequence-only and structure-dependent methods. **b**, Structural information distillation transfers structural information into sequence modality through modality bridging, thereby providing route guidance for interpretable prediction. **c**, Interaction matrix makes non-covalent interactions explicit through property modeling, thereby providing priors guidance for interpretable prediction.

related to protein interactions [15–19]. Srivamshi et al. [15] employed graph convolutional networks and an attention layer to explicitly encode the partner’s context in an antibody-antigen complex. While PINet [16] encoded proteins as surface point clouds with physicochemical properties and 3D geometry, predicting epitope-paratope in antibody-antigen. Another line of research is redesigning the complementarity-determining regions (CDRs) to get a broad-spectrum antibody. Shan et al. [20] developed a geometric neural network with attention mechanisms for antibody’s CDR sequences optimization. However, experimental structure determination methods, such as NMR spectroscopy and X-ray crystallography, prove to be both time-intensive and expensive, resulting in limited available high-quality structures of antibodies and their complexes. Although protein structure prediction methods [21–23] have made breakthrough progress, their inherent errors [24, 25] and the structural characteristics of antibodies [26, 27] bring obvious interference to AAI prediction. Naturally, high-quality data insufficiency presents an obstacle to training deep-learning models with ideal generalization capability. In contrast, sequence-only methods, which take advantage of extensive antibody sequence data, offer a more efficient framework for large-scale

88 antibody screening [28–33]. Earlier studies, such as ProABC [28], utilized a sequence-
89 only random forest algorithm to predict paratope residues, eliminating the need for
90 structured data to achieve accurate predictions. Parapred [29] employed a combina-
91 tion of local and global features, harnessing deep learning techniques to analyze AAI.
92 Marson et al. [30] introduced a convolutional neural network (MCNN) to predict the
93 antigen specificity of antibodies. DeepAAI [31] proposes dividing antigens and anti-
94 bodies into 'seen' and 'unseen' collections, utilizing graph neural networks to model
95 the issue of out-of-distribution (OOD) data. However, a common drawback shared
96 by these sequence-only methods is their limited interpretability and prediction per-
97 formance, primarily stemming from the alienation of one-dimensional sequences from
98 functionality.

99 In order to combine the advantages of both types of methods while avoiding the
100 disadvantages, it is essential to provide sensible 'sequence-to-function' guidance to
101 structure-free models. Thus, we propose S3AI (**S**tructure-**A**ssisted **A**ntibody-**A**ntigen
102 **I**nteraction **P**rediction), a deep-learning method that uses only sequences as inputs to
103 the inference phase.

104 The first form of guidance we introduce aims to establish an implicit route from
105 sequence to structure modalities. Modality bridging is a tangible way to build this
106 route (Fig.1b), where we automatically incorporate protein structural information
107 through a structural encoding module. By promoting the model's ability to map from
108 sequences to structural latent codes via contrastive learning, we break the barrier
109 between these distinct modalities. In this process, knowledge from the 3D structures
110 of massive antibodies is captured in the model parameters, allowing the model to
111 introduce implicit structural information automatically in case only sequence input
112 is used. The S3AI model incorporates two sequence feature extraction modules: one
113 dedicated to antigens and the other to antibodies. Considering the volume of available
114 structure and sequence data, structural information distillation is applied exclusively
115 to the antibody feature extraction branch. Subsequently, the derived parameters are
116 fine-tuned in several downstream tasks, aiming to enhance the performance of AAI
117 predictions.

118 Another pivotal guidance of S3AI is the explicit modeling of chemical priors
119 (Fig.1c). Recognizing the crucial role of non-covalent interactions in antibody-antigen
120 binding, we devise a module to capture chemical constraints accurately throughout
121 antigen-antibody docking. Beyond the features extracted from sequences using the pro-
122 tein language model, we generate various property maps of non-covalent interactions
123 from the sequences, adhering to universally applicable chemical rules. This provides
124 the model with insights into potential interaction formations through the integration of
125 chemical priors in the deep-learning framework. The concatenated interaction matrix
126 is passed through convolutional layers, facilitating effective feature aggregation and
127 providing the model with a rich source of localized information. This novel module
128 not only improves interpretability by affording a tangible linkage between molecular
129 interactions and predictive outcomes but also provides local features that synergize
130 with global features extracted in other stages.

131 Overall, S3AI is an interpretable deep-learning method that introduces route
132 and priors guidance towards understanding antibody-antigen interaction. Downstream

133 tasks for SARS-CoV-2 and HIV demonstrate the exceptional proficiency of S3AI in
134 predicting AAI, surpassing current state-of-the-art predictors. Importantly, S3AI cap-
135 tures universal patterns of antibody-antigen interactions, revealing antigen-specific
136 binding mechanisms and highlighting sub-regions important for the interaction. More-
137 over, S3AI's capability to operate without requiring structural input during the
138 inference phase positions it as an ideal solution for large-scale antibody optimization
139 and screening. Naturally, S3AI can be applied to the design of antibodies for various
140 targets, making the development of antibody drugs more precise and personalized.

141 2 Results

142 2.1 S3AI harnesses the property-driven architecture that 143 bridges structure to sequence

144 S3AI achieves unparalleled accuracy and throughput in predicting antibody-antigen
145 interactions by effectively integrating structural information with sequence input.
146 Prior to the advent of S3AI, methods focusing solely on sequence inputs attempted to
147 predict metrics related to AAI directly from the sequences of antibody-antigen pairs.
148 However, these approaches often fell short due to their lack of structural informa-
149 tion, which is crucial for understanding the nuances of interactions. Consequently, the
150 'routes' constructed are typically blind, intricate, and lack interpretability, making it
151 challenging to derive meaningful insights or predictions.

152 As shown in Fig.2a, S3AI, on the other hand, revolutionizes this approach by
153 actively guiding the mapping from antibody sequences to their structures, thereby
154 providing a more rational and coherent route for predicting AAI from sequence inputs.
155 The above strategy is here called 'structural information distillation', and its core
156 lies in training a structural encoder through contrastive learning to obtain structure-
157 enhanced features. In the teacher network, the antibody structure is processed by
158 a pre-trained structure network to extract structural features. In the student net-
159 work, the antibody sequence is fed to the protein language model (*i.e.* ESM [34] and
160 then encoded by a learnable structure encoder to obtain features that incorporate
161 structural information. Finally, the training manner of contrastive learning allows the
162 knowledge from the antibody structure to be transferred to the structure encoder.
163 This manner not only leverages the inherent sequence information but also enriches it
164 with structural data, enhancing the model's performance and the interpretability of
165 its predictions. By doing so, S3AI offers a more informed and precise framework for
166 understanding the intricate dynamics of antibody-antigen interactions.

167 Implicit modeling of AAI based on deep learning models is challenging because of
168 the complexity of molecular interactions, which can result in fundamental chemical
169 rules being poorly understood by the neural network. To address this challenge, we
170 propose the interaction matrix, which explicitly models chemical rules to introduce
171 crucial non-covalent interactions. As shown in Fig.2b, the sequences of an antibody
172 and an antigen are taken to calculate a property matrix containing non-covalent inter-
173 actions, including hydrogen bonding, electrostatic interactions, van der Waals forces,
174 and hydrophobic interactions. Take hydrogen bonding as an example, to construct a
175 H-bond map between an antibody and an antigen, we initially analyze their sequences




Fig. 2 **a**, Structural information distillation, in which the antibody structure information extracted by the structure network is distilled into antibody sequence modality, thereby training the structure encoder to obtain structure-enhanced features. **b**, Interaction matrix, in which the feature matrix is calculated by implicit sequence embeddings, and the property matrix contains the physicochemical properties calculated by chemical rules. **c**, The overall framework of S3AI. The input antibody sequence is extracted with structure-enhanced feature, and the interaction matrix is concatenated with it after passing through the CNN module. The concatenated feature is then input into the subsequent interaction prediction module for classification (neutralization or not) and regression (IC_{50} estimation) tasks.

176 to identify the number of hydrogen bond donors and acceptors for each amino acid.
 177 This step produces two vectors respectively, with lengths matching those of the anti-
 178 body and antigen, where each vector element indicates the count of hydrogen bond
 179 donors or acceptors at every amino acid position. Next, we compare the corresponding
 180 amino acids between the antibody and antigen, determining the minimum number of




Fig. 3 **a**, Prediction performance on integrated SARS-CoV-2 datasets. In both classification and regression tasks, S3AI outperforms state-of-the-art models across the board. **b**, Visualization of the impact of each module on the final concatenated features. The interaction matrix has a stronger impact on features than structural information distillation, and the joint use of the two modules achieves the best results.

181 available donors and acceptors for each pair. This results in two matrices, sized by the
 182 antibody and antigen sequence lengths. These matrices delineate the potential H-bond
 183 interactions between each amino acid pair, pinpointing regions with high interaction
 184 propensity. Furthermore, the sequences of both the antibody and the antigen are pro-
 185 cessed to extract embeddings using protein language model (ESM here), and these
 186 embeddings are then used to create a feature matrix. The above property matrix and
 187 feature matrix are concatenated to form the final interaction matrix, which contains
 188 both implicit and explicit interaction patterns.

189 With the support of structural information distillation and interaction matrix,
 190 the overall architecture of S3AI is shown in Fig.2c. The antibody and antigen
 191 sequences are passed through the protein language model (ESM here) to obtain cor-
 192 responding sequence features, in which the sequence features of core-domain of the
 193 antigen—determined by the antigen’s specific type—are adopted to form the feature
 194 matrix in the interaction matrix. The interaction matrix performs feature aggregation
 195 through the CNN module and is concatenated with the structure-enhanced feature of
 196 the antibody obtained through the structure encoder. The above-mentioned concate-
 197 nated features are input into the interaction prediction module for downstream tasks
 198 in the manner of multi-task learning, including the binary classification task of whether
 199 the antibody-antigen pair is neutralizing and the regression task of IC_{50} estimation.

200 2.2 S3AI significantly outperforms state-of-the-art models

201 In order to comprehensively evaluate the predictive ability of S3AI for AAI, we col-
202 lect SARS-CoV-2-related AAI data from previous studies and integrate them into
203 the largest dataset to date. As shown in Fig.3a, we perform a thorough comparison
204 with a series of models for antibody-antigen interaction prediction on regression tasks
205 and classification tasks, including MCNN [30], Parapred [29], Fast-Parapred [35], AG-
206 Fast-Parapred [35], PIPR [36], and ResPPI [37]. The detailed implementation can be
207 found in Supplementary information, Section S1. For the regression task of IC_{50} esti-
208 mation, S3AI significantly surpasses other models. It showcases superior performance
209 by achieving a Spearman correlation coefficient of 0.655 and a Pearson correlation
210 coefficient of 0.860. Compared to the best-performing existing model, this repre-
211 sents an improvement of approximately 13.3% in the Spearman correlation and about
212 7.1% in the Pearson correlation. For the classification task of neutralization, S3AI
213 still comprehensively outperforms other models, with an accuracy of 84.53% and an
214 MCC of 68.50%. Overall, S3AI shows comprehensive superiority in both regression
215 and classification tasks, stamping a new watermark for antibody-antigen interaction
216 prediction.

217 Structural information distillation and interaction matrix are crucial to the pre-
218 diction performance of S3AI, which is demonstrated in the visualization experiment
219 in Fig.3b and Table S4. Principal component analysis (PCA) is adopted to explore
220 the impact of each module on the concatenated features, *i.e.*, concatenations of
221 structure-enhanced features, and CNN-processed interaction matrix. Compared with
222 the visualization result on the far right without using the above two modules, the use
223 of any module results in better clustering of features, and the joint use of the two
224 modules achieves the best clustering effect. It is worth noting that the impact of the
225 interaction matrix on the clustering effect is stronger than that of structural informa-
226 tion distillation, which also confirms our hypothesis: it is difficult for neural networks
227 to directly understand intricate molecular interactions, and explicit chemical priors
228 modeling tends to provide a more accurate learning route.

229 2.3 S3AI's generalization performance for out-of-distribution 230 scenarios

231 Out-of-distribution (OOD) generalization is a common challenge faced by all deep
232 learning models. The above challenge is even more pronounced in the prediction sce-
233 nario of antibody-antigen interactions since most antibodies are 'unseen', *i.e.*, the
234 interactions of a large number of antibodies with any antigen are unknown [31]. For
235 natural antibodies, the antibody space produced when faced with viral invasion is very
236 large, which makes it time-consuming and costly to measure the interaction strength of
237 any antibody-antigen pair through wet-lab experiments. In addition, the interactions
238 of synthetic antibodies with antigens are also blind to us. Therefore, deep learning
239 models for antibody-antigen interaction prediction require ideal OOD generalization
240 capabilities.

241 Previous work proposed a deep-learning model, DeepAAI [31], specifically cus-
242 tomized to predict interactions of 'unseen' antibody-antigen pairs. In order to evaluate




Fig. 4 Generalization performance on HIV datasets. **a**, In the binary classification task of whether an antibody neutralizes HIV, S3AI comprehensively outperforms the state-of-the-art models specifically designed for out-of-distribution generalization of antibody-antigen interaction prediction, including model variants using PSSMs containing rich evolutionary information. **b**, In the regression task of IC_{50} estimation, S3AI outperforms most of the model variants, including all model variants that do not incorporate features with additional evolutionary information.

243 the generalization performance of S3AI, we adopt the original architecture of S3AI
 244 to compare performance with DeepAAI without adding any customized modules for
 245 OOD. The only adjustment is that we change the multi-task framework of S3AI to the
 246 same single-task framework as DeepAAI for a fair comparison. As shown in Fig.4a,
 247 in the neutralization classification task, S3AI without customization completely sur-
 248 passed all model variants of DeepAAI. On the regression task of IC_{50} estimation,
 249 S3AI surpasses most model variants, including the two model variants that only input
 250 sequences (Fig.4b). We can see that S3AI is slightly worse than the two model variants
 251 whose inputs contain position-specific scoring matrices (PSSMs) with evolutionary
 252 information. As an extremely time-consuming descriptor, PSSMs are calculated based
 253 on multiple sequence alignments and incorporate rich evolutionary information. How-
 254 ever, S3AI is a deep-learning method that only requires input sequences and does not
 255 contain additional homologous information, which may explain why its prediction per-
 256 formance on regression tasks is slightly worse than that of the model variants using
 257 PSSMs of DeepAAI. Overall, S3AI still surpasses the state-of-the-art OOD model
 258 under the same input configuration without special modifications to adapt to OOD
 259 scenarios. This indicates that S3AI has learned universal patterns of molecular interac-
 260 tions and thus accurately predicts interactions of never-before-seen antibody-antigen
 261 pairs.

262 2.4 S3AI captures the universal pattern of antigen-antibody 263 interactions

264 The aforementioned performance comparison demonstrates the excellent ability of
265 S3AI in predicting AAI, and indicates that it has learned universal patterns of molec-
266 ular interactions to a certain extent. What needs to be further explored is whether the
267 interaction pattern extracted by S3AI is consistent with the actual antibody neutral-
268 ization mechanism. To this end, we adopt a strategy of calculating the region effective
269 attribution, in which the higher the attribution of a region to the prediction result,
270 the more significant impact it has on the final prediction. There are basic modes of
271 neutralization between different antibodies and different antigens, the core of which
272 is that the Complementarity Determining Regions (CDRs) are responsible for bind-
273 ing to the antigen [38, 39]. As shown in Fig.5a, the region effective attributions of
274 all antibody samples are displayed, and the CDRs of most samples have more signifi-
275 cant attributions than other framework regions (FRs) in variable regions. The average
276 attributions of all samples show that the impact of CDRs is several times that of
277 FRs, which proves that CDR is the most important region for the interaction between
278 antibody and antigen. In Fig.5b, the region effective attributions of four antibody
279 samples are shown. The difference between these samples is that the attributions of
280 FRs to the interactions have different characteristics. In sample 1519, all FRs are pos-
281 itive attributions, while in sample 5401, it is exactly the opposite, that is, all FRs are
282 negative attributions. Furthermore, in sample 8485 and sample 27248, negative and
283 positive attributions coexist. The above phenomenon confirms a basic fact that the
284 attributions of FRs to the interactions are flexible and variable, which is caused by
285 the binding characteristics of different antibody-antigen pairs.

286 Moreover, CDR includes six sub-regions, namely CDR-L1, CDR-L2, CDR-L3,
287 CDR-H1, CDR-H2, and CDR-H3. A large number of previous works have agreed
288 that CDR-H3 is important for the interaction between antibodies and antigens, which
289 makes us very curious whether S3AI can capture this phenomenon [40–44]. As shown
290 in Fig.5c, sub-regions in the CDRs of four antibody samples are displayed. What
291 the four samples have in common is that CDR-H3 always tends to have signifi-
292 cant effective attribution, which is consistent with the above conclusion. Interestingly,
293 the impacts of sub-regions within the CDRs, aside from CDR-H3, are diverse and
294 irregular [41, 42, 45], which further highlights the complexity of AAI mechanism.

295 3 Discussion

296 Antibodies are important immune molecules that play a crucial role in the immune
297 process. The remarkable specificity of antibodies against antigens has led humans to
298 continue to explore technical routes to develop them into clinical drugs. With the
299 increasingly urgent demand for personalized and precision medicine, the research and
300 development of antibody drugs requires more efficient and high-precision technical
301 means. Computational methods, especially deep learning methods, have shown great
302 potential in antibody optimization or screening. However, the two current mainstream
303 methods for predicting AAI, namely structure-dependent and sequence-only methods,
304 have obvious shortcomings, which come from the scarcity of structural data and the



Fig. 5 **a**, Effective attributions of each region in variable regions to the predictions of antibody-antigen interactions. Among them, CDRs have the most significant average attribution, which is consistent with the basic mode of antibody neutralization. **b**, Effective attributions of four samples with different characteristics. The structures of antibody variable regions are colored according to the degree of attributions. **c**, Analysis of effective attributions within CDR regions of four samples. Different sub-regions in the CDRs are colored according to their attributions. Among them, CDR-H3 always tends to have a significant effective attribution, indicating that this sub-region is crucial for antibody neutralization, which is consistent with previous research conclusions.

305 alienation between sequence and function. In addition, the common difficulty faced by
306 the above two types of methods is that it is challenging for neural networks to under-
307 stand intricate molecular interactions. Therefore, the development of an interpretable
308 deep-learning model for AAI prediction that overcomes structural or sequence mode
309 constraints is of great significance for antibody engineering.

310 The first contribution of S3AI is to break the barrier between structure-dependent
311 and sequence-only methods. Predicting AAI based on sequences has a high task com-
312 plexity, which is rooted in the alienation route from sequence to structure and then
313 to function. This motivates us to utilize structural information implicitly, that is, to
314 incorporate knowledge from the protein structure modality to the sequence modal-
315 ity. In this work, we propose a strategy named structural information distillation to
316 achieve modality bridging. First, a teacher network with structure as input and a stu-
317 dent network with sequence as input are set up. The training manner of contrastive
318 learning is further used to store the information from the teacher network to the struc-
319 ture encoder. The structure encoder is capable of transforming sequence features into
320 structure-enhanced features, eliminating the need for input structure in the down-
321 stream task training and inference stages. In short, structural information distillation
322 effectively realizes cross-modal information transfer and promotes the establishment
323 of 'sequence-to-function' route.

324 S3AI's second contribution is the explicit modeling of chemical priors to guide
325 neural networks in understanding intricate molecular interactions. Antibody-antigen
326 interactions are primarily driven by non-covalent interactions, so we propose interac-
327 tion matrix to introduce the composite impact of hydrogen bonding, van der Waals
328 forces, electrostatic interaction, and hydrophobic interactions. In general, this inter-
329 action matrix makes up for the shortcomings of the implicit modeling of AAI. In
330 other words, explicit modeling of interaction patterns reduces the task complexity of
331 predicting functions directly from sequences.

332 The design of the above two modules ensures S3AI's excellent performance in
333 predicting AAI. In this work, we comprehensively examine the capabilities of S3AI,
334 including its generalization performance for out-of-distribution scenarios. S3AI not
335 only significantly surpasses the state-of-the-art models but also exhibits ideal OOD
336 generalization capabilities. Without any adjustments for the OOD task, S3AI still out-
337 performs all variants of the state-of-the-art model customized for OOD generalization
338 in predicting AAI in the classification task of neutralization or not. In the regres-
339 sion task of IC_{50} estimation, S3AI outperforms all model variants that only adopt
340 sequences as input in a fair comparison. The above prediction performance indicates
341 that S3AI has a certain degree of understanding of the basic patterns of molecu-
342 lar interactions, which facilitates its generalization for the prediction of unknown
343 antibody-antigen pairs. We further intuitively explore the ability of S3AI to capture
344 the universal pattern of AAI. Consistent with the antibody neutralization mechanism,
345 S3AI accurately identifies CDRs responsible for specific binding to antigens. Further-
346 more, the importance of sub-region CDR-H3 for AAI is also discovered by S3AI.
347 The above results demonstrate S3AI's awareness of molecular interaction mechanisms,
348 which is rooted in the introduction of route and priors guidance.

349 The potential of S3AI lies in the large-scale optimization and screening of antibod-
350 ies. The structure-free input mode in the inference stage breaks through the dilemma
351 of the scarcity of high-quality antibody structures, ensuring that antibody optimiza-
352 tion and screening are only performed at the sequence level and can be massively
353 parallel. This will greatly improve the efficiency of discovering immunologically active
354 or specific antibodies in the huge antibody space, thereby accelerating the develop-
355 ment of antibody drugs. However, the prediction performance of S3AI is limited by
356 the low quality of distilled structural information, which is caused by the predicted
357 antibody structures used in the structural information distillation module. It is fore-
358 seeable that in the future, as the scale of available high-quality antibody structures
359 increases, the structural information distillation module will be able to extract more
360 general and precise implicit structural information. In addition, further accurate mod-
361 eling of chemical rules is also a feasible way to improve the prediction performance
362 of S3AI. There is also an expectation for a lighter and faster prediction method that
363 could further hasten antibody engineering.

364 4 Methods

365 4.1 Data

366 4.1.1 Data for structural information distillation

367 The antibody structure data utilized for structural information distillation in this
368 study encompasses two main types: real antibody data collected from the SabDab [46]
369 and predicted antibody structure data derived from sequences using Igfold [47], which
370 is a deep learning model specifically designed for predicting antibody structures. For
371 the real antibody data, we exclude single-chain antibodies, entries with missing infor-
372 mation, those with formatting errors (such as redefined atoms), and sequences with
373 discontinuities within the chains. The structural data predicted by IgFold includes
374 paired antibodies from the OAS dataset, along with a selection of relevant antibodies
375 from the coronavirus.

376 4.1.2 SARS-CoV-2 data

377 Given the absence of comprehensive studies summarizing IC_{50} data across various
378 antibody-antigen pairs in the field, IC_{50} data are collected from several biological
379 studies [48–51] that measured and published IC_{50} values between SARS-CoV-2 or
380 its variants and human antibodies. These studies encompassed 18 different lineages,
381 including those that emerged after Omicron. We obtain mutations of each lineage
382 from outbreak.info [52, 53]. These mutations are then introduced into the spike pro-
383 tein sequences of the wild-type coronavirus, as obtained from GISAID [54]), thereby
384 generating the spike protein sequences for each lineage.

385 Manual standardization is necessary because the IC_{50} values originated from
386 diverse papers with varying experimental conditions. For example, the reporting of
387 negative sample values (where $IC_{50} \geq 10 \mu\text{g/ml}$) varies across studies, with some list-
388 ing them as '>>10', '>>100', or specifying a particular value over 10, or even a constant
389 value (e.g., 1000 $\mu\text{g/ml}$). In our study, we standardize all negative IC_{50} samples to

390 a uniform value of $10 \mu\text{g}/\text{ml}$. Similarly, we classify samples with $IC_{50} \geq 10 \mu\text{g}/\text{ml}$ as
391 non-neutralizing, while those with values below $10 \mu\text{g}/\text{ml}$ are deemed neutralizing.

392 Moreover, during the de-duplication process of antibody sequences, discrepancies
393 in IC_{50} values for the same antibody-antigen pair across different studies are observed.
394 Such inconsistent data are identified as errors and excluded to ensure dataset accu-
395 racy. We yield IC_{50} values for 29,483 pairs of coronavirus antigens and corresponding
396 antibodies.

397 4.1.3 HIV data

398 The HIV data used to test OOD performance in our study comes from the Com-
399 pile Analyze and Tally NAb Panels (CATNAP) at the Los Alamos HIV Database
400 (LANL) [55], as published by DeepAAI. We follow the dataset's split between 'seen'
401 and 'unseen' data, conducting OOD tests on the 'unseen' dataset.

402 4.2 Architecture overview

403 S3AI is built on the protein language model that takes paired antibody and antigen
404 sequences as input. The heavy and light chain sequences of the input antibody are
405 concatenated and then encoded by ESM. For antigens, the protein sequence is fed into
406 a separate ESM to produce the sequence feature:

$$\mathbf{Z}_{ab}^{seq} = \text{ESM}_{ab}(AB_H \oplus AB_L), \quad (1)$$

$$\mathbf{Z}_{ag}^{seq} = \text{ESM}_{ag}(AG), \quad (2)$$

407 where $AB_H = (ab_1, ab_2, \dots, ab_k)$ and $AB_L = (ab_{k+1}, ab_{k+2}, \dots, ab_m)$ represent the
408 sequences of the heavy and light chains of antibody, respectively, while $AG =$
409 $(ag_1, ag_2, \dots, ag_n)$ denotes the sequence of antigen. Structure encoder introduces
410 structural information to sequence features of antibody \mathbf{Z}_{ab}^{seq} , producing $\mathbf{Z}_{ab}^{seq2str}$ (see
411 Section 4.3). Meanwhile, the sequence features \mathbf{Z}_{ab}^{seq} , \mathbf{Z}_{ag}^{seq} , along with their respec-
412 tive sequences, are leveraged to generate the interaction matrix \mathbf{Z}^{inter} . This matrix
413 is subsequently processed by Convolutional Neural Network (CNN) module, aimed at
414 extracting interaction-related feature \mathbf{Z}^{conv} (refer to Section 4.4). Two different mul-
415 tilayer perceptrons (MLPs) are employed to subsequently process the concatenated
416 features, yielding predictions for both classification and regression tasks:

$$\hat{y}^{(cls)} = \sigma_{\text{sigmoid}}(\psi^{cls}(\mathbf{Z}_{ab}^{seq2str} \oplus \mathbf{Z}^{conv})), \quad (3)$$

$$\hat{y}^{(reg)} = \psi^{reg}(\mathbf{Z}_{ab}^{seq2str} \oplus \mathbf{Z}^{conv}), \quad (4)$$

417 where ψ^{cls} and ψ^{reg} represent the MLPs for classification and regression tasks,
418 respectively; \oplus denotes the concatenation operation on the final features.

419 4.3 Structural information distillation

420 The tertiary structure and sequence of antibodies can be considered two distinct
421 modalities. In AAI problems, the structural modality often contributes more signifi-
422 cantly than the sequence modality. However, the scarcity or even absence of structural
423 data in many application scenarios leads to performance loss. To address this chal-
424 lenge, we look towards a series of cross-modal distillation methods [56–58], which offer
425 a strategy to address the issue of missing modalities.

426 Building on this foundation and inspired by the recent advancements in the field
427 of molecular property prediction, notably the 3DInfomax [59], we leverage contrastive
428 learning to facilitate knowledge transfer between structural and sequence networks.
429 This process can be regarded as a form of cross-modal distillation technique.

430 Structural information distillation involves two networks: a teacher network $f_{str}(\cdot)$
431 that receives antibody structural inputs and outputs structural representations, and
432 a student network $f_{seq}(\cdot)$ that takes sequence inputs to generate sequence features.
433 The teacher network's weights are derived from pretraining on a protein structure
434 dataset and remain fixed throughout this process. The student network, comprised of
435 concatenated ESM and structure encoder, is tasked with extracting features from the
436 antibody sequence. During the training process, the student network's parameters are
437 updated, enabling it to learn how to incorporate structural information into sequence
438 features. For an antibody $x = (x^{seq}, x^{str})$ in a dataset, its sequence and structure are
439 input into $f_{seq}(\cdot)$ and $f_{str}(\cdot)$, respectively, yielding representations $z^{seq2str}$ and z^{str} .
440 The training objective at this stage is to maximize the similarity between representa-
441 tions of the same antibody $z_i^{seq2str}$ and z_i^{str} while minimizing the similarity between
442 unmatched representations $z_i^{seq2str}$ and z_j^{str} ($i \neq j$).

443 The similarity measurement function is defined as the cosine similarity, which is
444 given by the formula:

$$\text{sim}(z_i^{seq2str}, z_j^{str}) = \frac{z_i^{seq2str} \cdot z_j^{str}}{\|z_i^{seq2str}\| \|z_j^{str}\|}. \quad (5)$$

445 To guide this process, the NT-Xent (normalized temperature-scaled cross entropy)
446 loss is utilized[60]:

$$\mathcal{L}_{i,j} = -\log \frac{\exp(\text{sim}(z_i, z_j) / \tau)}{\sum_{k=1}^{2N} \mathbb{I}_{[k \neq i]} \exp(\text{sim}(z_i, z_k) / \tau)}, \quad (6)$$

447 where the indicator function $\mathbb{I}_{[k \neq i]}$ takes values from $\{0, 1\}$, is used to determine
448 whether k is not equal to i (evaluating to 1 if and only if $k \neq i$). Additionally, τ
449 represents a temperature parameter that adjusts the scale of the loss. The NT-Xent
450 loss is calculated for all positive pairs within a mini-batch, ensuring symmetry in the
451 evaluation of pairwise similarities.

452 We adopt the structural representation network proposed in [61] as our teacher
453 network, utilizing the pretrained weights they provided. The teacher network is solely
454 engaged in the process of structural information distillation, extracting representations
455 from structural data, and does not participate in the training or inference processes of
456 downstream tasks. The parameters of the structure encoder within the student network
457 are used for initialization and undergo further fine-tuning on downstream tasks.

458 4.4 Interaction matrix

459 Within the array of structure-independent methods, beyond the previously mentioned
460 challenge of diminished accuracy stemming from an absence of structural data, lies an
461 additional complication: the issue of ambiguous interpretability. In response, several
462 studies [62–65] have investigated the incorporation of attention mechanisms to enhance
463 interpretability. However, the intricate nature of molecular interactions presents a
464 significant challenge to the implicit modeling efforts of AAI through deep learning
465 models. Thus, given two sequences, the antibody $AB = (ab_1, ab_2 \dots, ab_m)$ and the
466 antigen $AG = (ag_1, ag_2, \dots, ag_n)$, we propose interaction matrix $\mathbf{Z}^{inter} \in \mathbb{R}^{m \times n \times d}$ to
467 capture the interaction pattern between antibody and antigen. The interaction matrix
468 is composed of two parts:

$$\mathbf{Z}^{inter} = [\mathbf{Z}^{\text{feat}}, \mathbf{Z}^{\text{prop}}]. \quad (7)$$

469 The feature matrix \mathbf{Z}^{feat} is derived from the element-wise multiplication of latent
470 codes, capturing sequence information:

$$z_{ij}^{\text{feat}} = h_i^{Ab} \odot h_j^{Ag}. \quad (8)$$

471 Here, h_i^{Ab} and h_j^{Ag} are the latent codes for the i^{th} amino acid in the antibody and the
472 j^{th} amino acid in the antigen, respectively.

473 For each type of non-covalent interaction, the property matrix \mathbf{Z}^{prop} introduces
474 specific channels, including hydrogen bonding, electrostatic interactions, van der Waals
475 forces, and hydrophobic interactions.

476 We first focus on hydrogen bonding, a fundamental interaction widely prevalent
477 across various protein-protein interactions. For each pair of amino acids, ab_i from the
478 antibody and ag_j from the antigen, the calculation for the H-bond matrix is as follows:

$$\begin{aligned} z_{ij}^{(1)} &= \min(P_{\text{acceptor}}(ab_i), P_{\text{donor}}(ag_j)), \\ z_{ij}^{(2)} &= \min(P_{\text{donor}}(ab_i), P_{\text{acceptor}}(ag_j)), \end{aligned} \quad (9)$$

479 where P_{acceptor} and P_{donor} represent the counts of hydrogen acceptor and donor
480 atoms, respectively, of an amino acid. This process iterates over each amino acid
481 pair between the two sequences, generating a comprehensive interaction profile that
482 captures potential hydrogen bonding.

483 Another type of important non-covalent interaction between antibodies and anti-
484 gens is electrostatic interactions. These interactions are primarily governed by the
485 charge properties of the amino acids. To incorporate electrostatic interactions into the
486 property matrix, a specific channel is introduced, which quantifies the potential for
487 electrostatic interactions between each pair of amino acids. The calculation for this
488 part of the property matrix can be represented as follows:

$$z_{ij}^{(3)} = \mathbb{I}[Q(ab_i) \cdot Q(ag_j) < 0], \quad (10)$$

489 where $Q(x)$ denotes the charge of amino acid x , which can be positive, negative, or
490 neutral. This binary representation streamlines the modeling of electrostatic interac-
491 tions by directly identifying when opposite charges are present between amino acids,

492 thus indicating potential attractive forces that can enhance the interaction. In this
493 context, only pairs of amino acids with opposite charges are considered to possibly
494 contribute to the interaction potential.

495 Building on the foundation laid by the analysis of hydrogen bonding and electro-
496 static interactions, we next turn our attention to van der Waals forces. While subtler
497 than the previously mentioned forces, van der Waals interactions play a crucial role
498 in the nuanced dance of molecular recognition, acting as the fine threads that help
499 weave the intricate tapestry of antibody-antigen interactions.

500 To capture potential van der Waals forces within interaction matrix, we intro-
501 duce an additional layer of analysis. Based on the relationship between distances and
502 interaction strengths between amino acids [66], we employ a Gaussian formula to
503 approximate the effect of distance on van der Waals forces, taking into account the
504 complementary nature of steric hindrance of amino acid side chains. The calculation
505 of this addition to our property matrix is as follows:

$$z_{ij}^{(4)} = \exp \left(-\frac{(V(ab_i) + V(ag_j) - V_0)^2}{2\sigma^2} \right). \quad (11)$$

506 Here, $V(x)$ denotes the van der Waals volume [67] of an amino acid x . V_0 and σ^2 are
507 derived from a Gaussian fit to the aggregate of possible amino acid pair volumes.

508 As the final piece of our interaction matrix, we leverage the hydropathy index [68]
509 to capture hydrophobic interactions. The calculation method is simple yet effective:

$$z_{ij}^{(5)} = 1 - \frac{|H(ab_i) - H(ag_j)|}{M}, \quad (12)$$

510 where $H(x)$ represents the hydropathy index of amino acid x . The term M stands
511 for the maximum absolute difference in hydropathy indices across all possible pairs of
512 amino acids, ensuring the subtraction operation yields a normalized score that reflects
513 the relative hydrophobic compatibility between ab_i and ag_j . This channel provides
514 information on hydrophobic interactions through a simple assessment of the differences
515 in hydrophobic and hydrophilic between interacting amino acids.

516 Given the approximations and simplifications involved in creating the property
517 matrix, as well as the complexity of actual interactions, we further extract features
518 from the interaction matrix using a CNN module. This module enriches the network
519 with local feature information. Through interpretability analysis (see Section 4.8),
520 we have also proven its effectiveness in capturing the patterns of antibody-antigen
521 interactions.

522 4.5 Multi-task focal loss

523 Due to the specificity of the interaction between antibodies and antigens, most of the
524 recorded antibody-antigen pairs do not exhibit neutralization. This has resulted in
525 an imbalance of positive and negative samples in our collected SARS-CoV-2 dataset.
526 Additionally, differences in fitness among different virus lineages lead to a non-uniform
527 data distribution at the lineage level. (see Supplementary information, Fig.S1) More-
528 over, since the IC_{50} values in the dataset come from different sources, and the

529 experimental conditions and methods cannot be guaranteed to be completely consistent,
530 the dataset also contains some unavoidable noise. To address these issues, we
531 have adopted a multi-task framework (see Section 4.2) along with the corresponding
532 focal loss [69, 70] for training downstream tasks. The overall loss consists of regression
533 and classification loss:

$$\mathcal{L} = \beta \mathcal{L}^{reg} + (1 - \beta) \mathcal{L}^{cls}, \quad (13)$$

534 where β is a weighting factor to balance the regression and classification tasks. The
535 regression part of focal loss is defined as:

$$\mathcal{L}^{reg} = \frac{1}{n} \sum_{i=1}^n (y_i - \hat{y}_i)^2. \quad (14)$$

536 For the binary classification neutralization prediction task, we adopt the classical focal
537 loss:

$$\mathcal{L}^{cls} = -\frac{1}{n} \sum_{i=1}^n (\alpha(1 - p_i)^\gamma \log(p_i) + (1 - \alpha)p_i^\gamma \log(1 - p_i)), \quad (15)$$

538 where $(1 - p_i)$ and p_i are the model's estimated probabilities for the class with label
539 $y = 0$ and $y = 1$, respectively; α is a weighting factor for the class; γ is the focusing
540 parameter that smoothly adjusts the rate at which easy examples are down-weighted.
541 (Supplementary information, Table.S8)

542 4.6 Evaluation metrics for regression and classification tasks

543 *Mean Absolute Error (MAE)*

544 MAE, conversely, measures the average magnitude of errors in a set of predictions
545 without considering their direction. It's calculated as the average of the absolute dif-
546 ferences between predicted and actual values, thus providing an intuitive measure of
547 prediction accuracy:

$$MAE = \frac{1}{N} \sum_{i=1}^N |y_i - \hat{y}_i|. \quad (16)$$

548 *Root Mean Square Error (RMSE)*

549 RMSE is a standard way to measure the error of a model in predicting quantitative
550 data. The formula for RMSE is given by:

$$RMSE = \sqrt{\frac{1}{N} \sum_{i=1}^N (y_i - \hat{y}_i)^2}, \quad (17)$$

551 where N is the number of observations, y_i is the actual value of an observation, and
552 \hat{y}_i is the predicted value.

553 **Pearson and Spearman Correlation**

554 IC_{50} values originate from wet-lab experiments across various batches and different
555 laboratories. Thus, given the diversity in experimental conditions, Spearman's rank
556 correlation coefficient (Spearman's ρ) is particularly apt for measuring the relation-
557 ship between ordinal variables, such as comparing the magnitudes of different IC_{50}
558 values. It assesses how well the relationship between two variables can be described
559 using a monotonic function, focusing on the ranks of values rather than their direct
560 magnitudes:

$$\rho = 1 - \frac{6 \sum d_i^2}{n(n^2 - 1)}, \quad (18)$$

561 where d_i is the difference between the ranks of corresponding values, and n is the
562 number of observations.

563 We also consider Pearson's correlation coefficient (Pearson's r) for its ability to
564 measure the linear correlation between two variables, offering a comprehensive analysis
565 when the data distribution permits:

$$r = \frac{\sum (x_i - \bar{x})(y_i - \bar{y})}{\sqrt{\sum (x_i - \bar{x})^2 \sum (y_i - \bar{y})^2}}, \quad (19)$$

566 where x_i and y_i are the individual sample points indexed with i , \bar{x} and \bar{y} are the
567 sample means.

568 Considering the variability in IC_{50} data due to different experimental setups,
569 Spearman's ρ becomes a more suitable choice for evaluating the ordinal relationship
570 between IC_{50} values, providing a robust measure against the non-uniformity of data
571 collection methods. Pearson's r complements this by quantifying the degree of linear
572 relationship where applicable, together offering a nuanced approach to assess predictive
573 accuracy in the context of IC_{50} value prediction.

574 **Accuracy, F1 Score, and Matthews Correlation Coefficient (MCC)**

575 In evaluating binary classification models, especially with imbalanced datasets like
576 the SARS-CoV-2 datasets, accuracy alone can be misleading. Thus, we supplement it
577 with the F1 Score and the Matthews Correlation Coefficient (MCC). The F1 Score,
578 calculated as the harmonic mean of precision p (correct positive predictions out of
579 all positive predictions) and recall r (correct positive predictions out of all actual
580 positives), offers a balanced metric:

$$F1 = 2 \cdot \frac{p \cdot r}{p + r}. \quad (20)$$

581 MCC further provides a comprehensive measure by accounting for all aspects of the
582 confusion matrix, capturing the quality of binary classifications beyond the limitations
583 of accuracy and F1 Score. This approach ensures a more accurate assessment of model
584 performance in handling the skewed class distribution typical of the SARS-CoV-2
585 dataset.

$$MCC = \frac{TP \times TN - FP \times FN}{\sqrt{(TP + FP)(TP + FN)(TN + FP)(TN + FN)}}, \quad (21)$$

586 where TP is the number of true positives, TN is the number of true negatives, FP is
587 the number of false positives, and FN is the number of false negatives.

588 ***Precision–Recall Area Under the Curve (PC-AUC) and Area Under the
589 Receiver Operating Characteristic (ROC-AUC)***

590 PR-AUC measures the trade-off between precision and recall across different thresh-
591 olds. It is particularly valuable in the SARS-CoV-2 datasets, where positive samples
592 (neutralizing pairs) are much less common than negative ones.

593 ROC-AUC evaluates how well the model distinguishes between neutralizing and
594 non-neutralizing pairs over various threshold settings. It plots the true positive rate
595 (recall) against the false positive rate (the ratio of incorrectly identified negatives) to
596 show the model's discrimination capability.

597 **4.7 Module ablation study and principal component analysis**

598 To further investigate and analyze the impact of structural information distillation
599 and interaction matrix on model performance, we conduct module ablation study and
600 PCA analysis on the final concatenated features.

601 We employ four configurations of the model: the original S3AI, one without struc-
602 tural information distillation, one without interaction matrix, and one without both
603 components. For the version without structural information distillation, we randomly
604 initialize the structural encoding module. For the variant lacking interaction matrix,
605 we pool the sequence features of the antibody and antigen along their length, con-
606 catenate them with the other final features, and then feed them into the interaction
607 prediction module for prediction. All models are trained under identical settings. After
608 training, we use PCA analysis to visualize the concatenated features of the best check-
609 point for each model on all samples in the test set. The final performance of ablation
610 study is presented in Table.S4.

611 **4.8 Region effective attribution calculation**

612 ***Attribution evaluation***

613 We use the Shapley value [71] to measure the attribution of the regions in the input
614 antibody to the prediction result. The Shapley value is a renowned game-theoretic
615 metric for assessing the attribution/importance of each input variable to the output
616 of the deep learning model. It has been recognized as the sole attribution method
617 that adheres to the axioms of anonymity, symmetry, dummy, additivity, and efficiency.
618 Accordingly, the Shapley value [72] of the i -th variable is computed as follows:

$$\phi(i) = \sum_{S \subseteq N \setminus \{i\}} \frac{|S|!(r - |S| - 1)!}{r!} \cdot [v(S \cup \{i\}) - v(S)], \quad (22)$$

619 where N denotes the set of variables and $|\cdot|$ denotes the cardinality of the set. Here,
620 we use $v(S)$ to simplify the notation of $v(x_S)$, and $v(x_S)$ denotes the model output
621 on a masked sample x_S . In the masked sample x_S , variables in S are present, and
622 variables in $N \setminus S$ are masked. In this way, $v(\emptyset)$ represents the model output when all

623 input variables are masked, and $v(N)$ denotes the model output on the original input
624 sample x .

625 ***Attribution of FRs and entire CDRs***

626 As the first step of estimating the attribution of the CDRs, we visualize the effects of
627 the entire CDRs on the prediction result.

628 For an input antibody AB, let $\mathbf{Z}^{inter} \in \mathbb{R}^{m \times n \times d}$ denote the interaction matrix,
629 where m , n , and d denote the length of the antibody AB, the length of the antigen
630 AG and channel number of the interaction matrix, respectively. We select the feature
631 of the entire CDRs as a single variable and divide the remained feature of FRs in
632 \mathbf{Z}^{inter} into t continuous regions. These regions and the CDRs are selected as $t + 1$
633 input variables, which consist of the input variable set N , to calculate the Shapley
634 value. Then, we set $v(N)$ as the prediction output for antibody-antigen interactions,
635 and $v(S)$ denotes the prediction output when the variable in $N \setminus S$ is masked.

636 ***Attribution of each CDR sub-region***

637 After calculating the attribution of the entire CDRs, we estimate the attribution of
638 each CDR sub-region.

639 Given an intermediate-layer feature of an input antibody, the entire CDRs consist
640 of 6 parts: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3. We select
641 the feature of these 6 parts as input variables, which consist of the input variable set
642 N . Then, we set $v(N)$ as the attribution of the entire CDRs in this input antibody
643 AB and $v(S)$ denotes the attribution of the entire CDRs when the variable in $N \setminus S$
644 is masked.

645 ***Mask method***

646 When we calculate the prediction output $v(S)$ on a masked input antibody, we system-
647 atically mask the selected variables in $N \setminus S$, which represent features in the interaction
648 matrix, and observe their impact on the model's output. This method involves iter-
649 atively masking each feature while measuring the change in the model's predictions.
650 By comparing the model's output with masked and present variables, Shapley val-
651 ues can be calculated to quantify the feature's contribution to the prediction. This
652 method requires a faithful baseline value to mask the variable, which does not provide
653 additional prior information and does not cause the masked feature to be out of the
654 distribution of the original features in the interaction matrix.

655 For the attribution of the entire CDRs, the baseline value to mask the variable
656 is set as the variable's average feature vector across the dataset, which is a widely
657 used method to set the baseline value, providing a reference point for evaluating the
658 significance of individual features.

659 For the attribution of each CDR sub-region, since $v(N)$ is the attribution of the
660 entire CDRs, we calculate the masked output $v(S)$ by replacing the features of the
661 regions in the CDRs that belong to $N \setminus S$ with baseline values when calculating the
662 attribution entire CDRs. The baseline value to mask the variable is set as the variable's
663 average feature vector across the dataset.

664 **Variable selection**

665 In order to encourage greater faithful effective attribution, we generate many parti-
666 tions of variables for calculating the Shapley value. In the selection of Shapley values
667 for the attribution of the entire CDRs, the process involves randomly selecting con-
668 tiguous regions from the input antibody after choosing CDRs as a whole, and for the
669 attribution of each CDR sub-region, we also use these randomly selected regions to
670 get several attribution value outputs.

671 Besides, these remaining regions can be randomly sampled in various sizes to create
672 different scales of variables. These selected regions form the variables for computing
673 the Shapley value. Through various combinations of these selections, attributions are
674 calculated for each variable, and the average result across all selections represents the
675 final attribution of the entire CDRs.

676 By calculating the attribution for each variable and averaging the results across
677 all partitions, we obtain a comprehensive assessment of the entire CDRs' attribution
678 to the prediction outcome. Additionally, by averaging the attribution values outputs
679 $\{v(S)\}$ from all partitions, this approach ensures a comprehensive evaluation of the
680 attribution for each CDR sub-region.

681 **Data availability**

682 The SabDab data is available at <https://opig.stats.ox.ac.uk/webapps/sabdab-sabpred/sabdab>. The processed HIV data is freely available at
683 <https://github.com/enai4bio/DeepAAI>. SARS-CoV-2 data can be downloaded from
684 <https://github.com/stau-7001/S3AI>.

686 **Code availability**

687 Relevant code and models are available at <https://github.com/stau-7001/S3AI>.

688 **References**

- 689 [1] Jerne, N. K. The immune system. *Scientific American* **229**, 52–63 (1973).
- 690 [2] Nimmerjahn, F. & Ravetch, J. V. Antibody-mediated modulation of immune
691 responses. *Immunological reviews* **236**, 265–275 (2010).
- 692 [3] Parkin, J. & Cohen, B. An overview of the immune system. *The Lancet* **357**,
693 1777–1789 (2001).
- 694 [4] Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Strategies and challenges for
695 the next generation of antibody–drug conjugates. *Nature reviews Drug discovery*
696 **16**, 315–337 (2017).
- 697 [5] Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody–
698 drug conjugates for cancer therapy. *Nature Reviews Clinical Oncology* **18**, 327–344
699 (2021).

700 [6] Bustamante, C. D., De La Vega, F. M. & Burchard, E. G. Genomics for the
701 world. *Nature* **475**, 163–165 (2011).

702 [7] Patterson, S. D. & Aebersold, R. H. Proteomics: the first decade and beyond.
703 *Nature genetics* **33**, 311–323 (2003).

704 [8] Varadé, J., Magadán, S. & González-Fernández, Á. Human immunology and
705 immunotherapy: main achievements and challenges. *Cellular & Molecular*
706 *Immunology* **18**, 805–828 (2021).

707 [9] Krzyszczyk, P. *et al.* The growing role of precision and personalized medicine for
708 cancer treatment. *Technology* **6**, 79–100 (2018).

709 [10] Johnson, K. B. *et al.* Precision medicine, ai, and the future of personalized health
710 care. *Clinical and translational science* **14**, 86–93 (2021).

711 [11] Lee, C. M., Iorno, N., Sierro, F. & Christ, D. Selection of human antibody
712 fragments by phage display. *Nature protocols* **2**, 3001–3008 (2007).

713 [12] Butler, J. E. Enzyme-linked immunosorbent assay. *Journal of immunoassay* **21**,
714 165–209 (2000).

715 [13] Muñoz-Fontela, C. *et al.* Animal models for covid-19. *Nature* **586**, 509–515 (2020).

716 [14] Schmidt, F. *et al.* Measuring sars-cov-2 neutralizing antibody activity using pseu-
717 dotyped and chimeric viruses. *Journal of Experimental Medicine* **217**, e20201181
718 (2020).

719 [15] Pittala, S. & Bailey-Kellogg, C. Learning context-aware structural representations
720 to predict antigen and antibody binding interfaces. *Bioinformatics* **36**, 3996–4003
721 (2020).

722 [16] Dai, B. & Bailey-Kellogg, C. Protein interaction interface region prediction by
723 geometric deep learning. *Bioinformatics* 2580–2588 (2021). URL <http://dx.doi.org/10.1093/bioinformatics/btab154>.

725 [17] Myung, Y., Pires, D. E. & Ascher, D. B. Csm-ab: graph-based antibody–antigen
726 binding affinity prediction and docking scoring function. *Bioinformatics* **38**, 1141–
727 1143 (2022).

728 [18] Yang, Y. X., Huang, J. Y., Wang, P. & Zhu, B. T. Area-affinity: A web server
729 for machine learning-based prediction of protein–protein and antibody–protein
730 antigen binding affinities. *Journal of Chemical Information and Modeling* **63**,
731 3230–3237 (2023).

732 [19] Yang, Y. X., Wang, P. & Zhu, B. T. Binding affinity prediction for antibody–
733 protein antigen complexes: A machine learning analysis based on interface and
734 surface areas. *Journal of Molecular Graphics and Modelling* **118**, 108364 (2023).

735 [20] Shan, S. *et al.* Deep learning guided optimization of human antibody against
736 SARS-CoV-2 variants with broad neutralization. *Proceedings of the National
737 Academy of Sciences* **119**, e2122954119 (2022).

738 [21] Jumper, J. *et al.* Highly accurate protein structure prediction with alphafold.
739 *Nature* **596**, 583–589 (2021).

740 [22] Lin, Z. *et al.* Evolutionary-scale prediction of atomic-level protein structure with
741 a language model. *Science* **379**, 1123–1130 (2023).

742 [23] Evans, R. *et al.* Protein complex prediction with alphafold-multimer. *bioRxiv*
743 2021–10 (2021).

744 [24] Yin, R., Feng, B. Y., Varshney, A. & Pierce, B. G. Benchmarking alphafold for
745 protein complex modeling reveals accuracy determinants. *Protein Science* **31**,
746 e4379 (2022).

747 [25] Stevens, A. O. & He, Y. Benchmarking the accuracy of alphafold 2 in loop
748 structure prediction. *Biomolecules* **12**, 985 (2022).

749 [26] Ruffolo, J. A., Sulam, J. & Gray, J. J. Antibody structure prediction using
750 interpretable deep learning. *Patterns* **3** (2022).

751 [27] Edelman, G. M. Antibody structure and molecular immunology. *Science* **180**,
752 830–840 (1973).

753 [28] Olimpieri, P. P., Chailyan, A., Tramontano, A. & Marcatili, P. Prediction of
754 site-specific interactions in antibody-antigen complexes: the proabc method and
755 server. *Bioinformatics* **29**, 2285–2291 (2013).

756 [29] Liberis, E., Veličković, P., Sormanni, P., Vendruscolo, M. & Liò, P. Parapred:
757 antibody paratope prediction using convolutional and recurrent neural networks.
758 *Bioinformatics* **34**, 2944–2950 (2018).

759 [30] Mason, D. M. *et al.* Optimization of therapeutic antibodies by predicting anti-
760 gen specificity from antibody sequence via deep learning. *Nature Biomedical
761 Engineering* **5**, 600–612 (2021).

762 [31] Zhang, J. *et al.* Predicting unseen antibodies' neutralizability via adaptive graph
763 neural networks. *Nature Machine Intelligence* **4**, 964–976 (2022).

764 [32] Huang, Y., Zhang, Z. & Zhou, Y. Abagintpre: A deep learning method for pre-
765 dicting antibody-antigen interactions based on sequence information. *Frontiers
766 in Immunology* **13**, 1053617 (2022).

767 [33] Yuan, Y., Chen, Q., Mao, J., Li, G. & Pan, X. Dg-affinity: predicting antigen-
768 antibody affinity with language models from sequences. *BMC bioinformatics* **24**,
769 430 (2023).

770 [34] Lin, Z. *et al.* Language models of protein sequences at the scale of evolution
771 enable accurate structure prediction. *bioRxiv* (2022).

772 [35] Deac, A., Veličković, P. & Sormanni, P. Attentive cross-modal paratope
773 prediction. *Journal of Computational Biology* **26**, 536–545 (2019).

774 [36] Chen, M. *et al.* Multifaceted protein–protein interaction prediction based on
775 siamese residual rcnn. *Bioinformatics* **35**, i305–i314 (2019).

776 [37] Lu, S., Hong, Q., Wang, B. & Wang, H. Efficient resnet model to predict protein–
777 protein interactions with gpu computing. *IEEE Access* **8**, 127834–127844 (2020).

778 [38] Davies, D. R. & Cohen, G. H. Interactions of protein antigens with antibodies.
779 *Proceedings of the National Academy of Sciences* **93**, 7–12 (1996).

780 [39] Padlan, E. A., Abergel, C. & Tipper, J. P. Identification of specificity-determining
781 residues in antibodies. *The FASEB journal* **9**, 133–139 (1995).

782 [40] Shirai, H., Kidera, A. & Nakamura, H. Structural classification of cdr-h3 in
783 antibodies. *FEBS letters* **399**, 1–8 (1996).

784 [41] Miller, N. L., Clark, T., Raman, R. & Sasisekharan, R. Learned features of
785 antibody-antigen binding affinity. *Frontiers in Molecular Biosciences* **10**, 1112738
786 (2023).

787 [42] Osajima, T. & Hoshino, T. Roles of the respective loops at complementarity
788 determining region on the antigen-antibody recognition. *Computational Biology
789 and Chemistry* **64**, 368–383 (2016).

790 [43] Tsuchiya, Y. & Mizuguchi, K. The diversity of h 3 loops determines the antigen-
791 binding tendencies of antibody cdr loops. *Protein Science* **25**, 815–825 (2016).

792 [44] Aburatani, T., Ueda, H. & Nagamune, T. Importance of a cdr h3 basal residue in
793 vh/vl interaction of human antibodies. *The journal of biochemistry* **132**, 775–782
794 (2002).

795 [45] Flyak, A. I. *et al.* An ultralong cdrh2 in hcv neutralizing antibody demonstrates
796 structural plasticity of antibodies against e2 glycoprotein. *Elife* **9**, e53169 (2020).

797 [46] Dunbar, J. *et al.* Sabdab: the structural antibody database. *Nucleic acids research*
798 **42**, D1140–D1146 (2014).

799 [47] Ruffolo, J. A., Chu, L.-S., Mahajan, S. P. & Gray, J. J. Fast, accurate antibody
800 structure prediction from deep learning on massive set of natural antibodies.
801 *Nature communications* **14**, 2389 (2023).

802 [48] Cao, Y. *et al.* Imprinted sars-cov-2 humoral immunity induces convergent omicron
803 rbd evolution. *Nature* **614**, 521–529 (2023).

804 [49] Cao, Y. *et al.* Omicron escapes the majority of existing sars-cov-2 neutralizing
805 antibodies. *Nature* **602**, 657–663 (2022).

806 [50] Cho, A. *et al.* Anti-sars-cov-2 receptor-binding domain antibody evolution after
807 mrna vaccination. *Nature* **600**, 517–522 (2021).

808 [51] Wang, Z. *et al.* mrna vaccine-elicited antibodies to sars-cov-2 and circulating
809 variants. *Nature* **592**, 616–622 (2021).

810 [52] Gangavarapu, K. *et al.* Outbreak. info genomic reports: scalable and dynamic
811 surveillance of sars-cov-2 variants and mutations. *Nature Methods* **20**, 512–522
812 (2023).

813 [53] Tsueng, G. *et al.* Outbreak. info research library: A standardized, searchable
814 platform to discover and explore covid-19 resources. *Nature Methods* **20**, 536–540
815 (2023).

816 [54] Khare, S. *et al.* Gisaid's role in pandemic response. *China CDC weekly* **3**, 1049
817 (2021).

818 [55] Yoon, H. *et al.* Catnap: a tool to compile, analyze and tally neutralizing antibody
819 panels. *Nucleic acids research* **43**, W213–W219 (2015).

820 [56] Zhang, L., Chen, Z. & Qian, Y. Knowledge distillation from multi-modality to
821 single-modality for person verification. *Proc. Interspeech 2021* 1897–1901 (2021).

822 [57] Afouras, T., Chung, J. S. & Zisserman, A. *Asr is all you need: Cross-modal
823 distillation for lip reading*, 2143–2147 (IEEE, 2020).

824 [58] Jin, Y. *et al.* *Cross-modal distillation for speaker recognition*, Vol. 37, 12977–12985
825 (2023).

826 [59] Stärk, H. *et al.* *3d infomax improves gnns for molecular property prediction*, Vol.
827 162 of *Proceedings of Machine Learning Research*, 20479–20502 (PMLR, 2022).

828 [60] Chen, T., Kornblith, S., Norouzi, M. & Hinton, G. E. *A simple framework for
829 contrastive learning of visual representations*, Vol. 119 of *Proceedings of Machine
830 Learning Research*, 1597–1607 (PMLR, 2020).

831 [61] Guo, Y., Wu, J., Ma, H. & Huang, J. *Self-supervised pre-training for protein
832 embeddings using tertiary structures*, 6801–6809 (AAAI Press, 2022).

833 [62] Hosseini, S. & Ilie, L. Pithia: Protein interaction site prediction using multiple
834 sequence alignments and attention. *International Journal of Molecular Sciences*
835 **23**, 12814 (2022).

836 [63] Chen, L. *et al.* Transformercpi: improving compound–protein interaction pre-
837 diction by sequence-based deep learning with self-attention mechanism and label

838 reversal experiments. *Bioinformatics* **36**, 4406–4414 (2020).

839 [64] Li, M., Lu, Z., Wu, Y. & Li, Y. Bacpi: a bi-directional attention neural network
840 for compound–protein interaction and binding affinity prediction. *Bioinformatics*
841 **38**, 1995–2002 (2022).

842 [65] Chen, C., Wu, T., Guo, Z. & Cheng, J. Combination of deep neural network with
843 attention mechanism enhances the explainability of protein contact prediction.
844 *Proteins: Structure, Function, and Bioinformatics* **89**, 697–707 (2021).

845 [66] Chari, R., Jerath, K., Badkar, A. V. & Kalonia, D. S. Long-and short-range
846 electrostatic interactions affect the rheology of highly concentrated antibody
847 solutions. *Pharmaceutical research* **26**, 2607–2618 (2009).

848 [67] Zamyatnin, A. Protein volume in solution. *Progress in biophysics and molecular
849 biology* **24**, 107–123 (1972).

850 [68] Eisenberg, D. Three-dimensional structure of membrane and surface proteins.
851 *Annual review of biochemistry* **53**, 595–623 (1984).

852 [69] Lin, T.-Y., Goyal, P., Girshick, R., He, K. & Dollár, P. *Focal loss for dense object
853 detection*, 2980–2988 (2017).

854 [70] Nie, Z. *et al.* Evolution-guided large language model is a predictor of virus
855 mutation trends. *bioRxiv* 2023–11 (2023).

856 [71] Lundberg, S. M. & Lee, S. Guyon, I. *et al.* (eds) *A unified approach to interpreting
857 model predictions*. (eds Guyon, I. *et al.*) *Advances in Neural Information Processing
858 Systems 30: Annual Conference on Neural Information Processing Systems
859 2017, December 4-9, 2017, Long Beach, CA, USA*, 4765–4774 (2017).

860 [72] Shapley, L. S. *et al.* A value for n-person games (1953).

861 Acknowledgements

862 This work is financially supported by the National Key R&D Program of China
863 (No. 2022ZD0118201, 2020YFA0908100, 2023YFF1204401), Natural Science Founda-
864 tion of China (No. 61972217, 32071459, 62176249, 62006133, 62271465, 61825101,
865 62088102, 21991132, 21925102, 92056118, 22331003, 22301010), Shenzhen Medical
866 Research Fund (No. B2302037), and Beijing National Laboratory for Molecular Sci-
867 ences (BNLMS-CXXM-202006). The work is also supported by the National Center
868 for Protein Sciences at Peking University. W.-B.Z. acknowledges Bayer Pharma
869 for the Bayer Investigator Award. We appreciate the support of AI for Science
870 (AI4S)-Preferred Program, Peking University Shenzhen Graduate School, China.

⁸⁷¹ **Competing interests**

⁸⁷² The authors declare no competing interests.

873 Supplementary information

874 S1 Baseline methods

875 In conducting the comparative experiments, as the models utilized for comparison are
876 not all originally designed for IC_{50} regression or classification tasks, we implement sev-
877 eral essential adjustments. For the Parapred-series models (Parapred, Fast-Parapred,
878 and AG-Fast-Parapred), originally intended for predicting binding sites, as well as the
879 PPI prediction models PIPR and ResPPI, we modify their output head to replicate
880 the structure of S3AI, thereby enabling the prediction of IC_{50} values and binary clas-
881 sification outputs. For MCNN, in addition to the modifications mentioned above, we
882 incorporate a module with the same architecture as the one originally designed for
883 processing antibody inputs. This new module is designed for handling antigen inputs,
884 allowing MCNN to accommodate the diverse antigen inputs in the dataset. All models
885 are trained using the same multitask focal loss as employed by S3AI.

886 S2 Overview of SARS-CoV-2 data




Fig. S1 The distribution of IC_{50} values across different SARS-CoV-2 lineages

887 **S3 Results for SARS-CoV-2 test set**

Metric	MCNN	ResPPI	Parapred	Fast-parapred	AG-fast-parapred	PIPR	S3AI
MAE ↓	0.911	0.818	0.967	0.981	1.171	1.045	0.605
RMSE ↓	1.605	1.475	1.524	1.467	1.697	1.673	1.243
Spearmanr ↑	0.525	0.579	0.566	0.575	0.528	0.511	0.655
Pearsonr ↑	0.756	0.803	0.780	0.802	0.743	0.731	0.860
Accuracy ↑	0.780	0.821	0.801	0.815	0.767	0.768	0.845
F1 score↑	0.844	0.863	0.851	0.859	0.837	0.836	0.870
PR-AUC ↑	0.852	0.898	0.888	0.917	0.881	0.843	0.945
ROC-AUC ↑	0.811	0.874	0.857	0.884	0.846	0.805	0.921
MCC ↑	0.523	0.612	0.564	0.597	0.499	0.492	0.685

Table S1 Performance of models on SARS-CoV-2 test set.

888 **S4 Results for HIV test set**

Model	Accuracy ↑	F1 score ↑	PR-AUC ↑	ROC-AUC ↑	MCC ↑
DeepAAI (sequence)	0.768	0.744	0.830	0.851	0.533
DeepAAI (k-mer+PSSM)	0.768	0.740	0.828	0.845	0.533
DeepAAI (PSSM+sequence)	0.777	0.757	0.842	0.858	0.552
DeepAAI (k-mer+sequence)	0.777	0.752	0.844	0.862	0.552
DeepAAI (k-mer+PSSM+sequence)	0.776	0.749	0.841	0.859	0.549
S3AI	0.807	0.774	0.861	0.880	0.606

Table S2 Classification Performance of models on OOD test (HIV unseen test set for classification).

Model	MSE ↓	MAE ↓
DeepAAI (sequence)	5.15	1.68
DeepAAI (k-mer+PSSM)	3.28	1.36
DeepAAI (PSSM + sequence)	3.63	1.37
DeepAAI (k-mer+sequence)	4.99	1.66
DeepAAI (k-mer+PSSM+sequence)	4.98	1.66
S3AI	4.39	1.59

Table S3 Regression Performance of models on OOD test (HIV unseen test set for regression).

889 **S5 Results for module ablation study**

Model	Baseline	Structural Information Distillation	Interaction Matrix	S3AI
MAE ↓	0.955	0.899	0.645	0.605
RMSE ↓	1.634	1.578	1.262	1.243
Spearmanr ↑	0.544	0.552	0.626	0.655
Pearsonr ↑	0.752	0.761	0.854	0.860
Accuracy ↑	0.791	0.799	0.837	0.845
F1 score ↑	0.838	0.847	0.866	0.870
PR-AUC ↑	0.876	0.881	0.936	0.945
ROC-AUC ↑	0.836	0.842	0.909	0.921
MCC ↑	0.545	0.559	0.660	0.685

Table S4 Results for module ablation study, including four configurations of the model: the original S3AI, one without structural information distillation (Interaction Matrix), one without interaction matrix (Structural Information Distillation), and one without both components (Baseline).

890 **S6 Region effective attribution**

FR1	FR2	FR3	FR4	FR5	FR6	CDRs
1.601e-02	5.857e-02	9.106e-03	9.721e-02	2.373e-02	4.919e-02	1.526e-01

Table S5 Average region effective attribution of FRs and entire CDRs in Fig.5a

Sample	FR1	FR2	FR3	FR4	FR5	FR6	CDRs
1519	3.180e-02	9.545e-02	5.059e-02	9.721e-02	3.774e-02	9.212e-02	1.978e-01
5401	-7.455e-04	-1.046e-03	-4.464e-04	-4.709e-04	-1.063e-03	-1.361e-03	4.985e-03
8488	4.115e-02	-8.567e-02	-8.890e-02	5.021e-02	-9.608e-02	-1.039e-01	2.902e-01
27248	-9.986e-03	5.151e-02	1.751e-02	-1.747e-02	4.270e-02	1.611e-02	6.545e-02

Table S6 Region effective attribution of FRs and entire CDRs in Fig.5b

Sample	CDR-L1	CDR-L2	CDR-L3	CDR-H1	CDR-H2	CDR-H3
44	-9.326e-03	-1.902e-02	-3.844e-02	-1.459e-02	3.083e-02	1.128e-01
60	2.932e-02	-3.881e-03	2.634e-02	-3.949e-02	2.932e-02	6.291e-02
68	-5.323e-02	1.369e-01	-2.485e-01	1.823e-01	3.043e-01	2.035e-01
93	3.145e-02	3.879e-02	5.390e-02	-5.350e-02	-7.830e-02	1.449e-01

Table S7 Region effective attribution of CDRs in Fig.5c

891 **S7 Hyperparameters**

Hyperparameter	Value
Learning rate	0.0001
Number of epochs	200
γ	1
β	0.8
ESM embedding dim	640 (150M)
Dropout rate	0.6
Convolution layers	3
Kernel size	3

Table S8 Hyperparameters of the model